• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Abstract 303: Adoption of the Novel Oral Anticoagulant Dabigatran in Patients with Atrial Fibrillation Receiving Warfarin in Community Practice: Findings from ORBIT AF Poster Session III
Conclusions: Patients receiving warfarin who were switched to dabigatran were younger, with lower CHADS2 scores, better kidney function, and less concomitant cardiovascular disease than those not switched. This conservative transition pattern suggests greater physician emphasis on bleeding avoidance than on stroke risk reduction.
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: Holmes, D. N., Steinberg, B. A., Piccini, J. P., Ansell, J., Chang, P., Fonarow, G. C., Gersh, B., Mahaffey, K., Kowey, P., Thomas, L., Peterson, E. D., Hylek, E. Tags: Poster Session III Source Type: research

Abstract 315: Feasibility of outpatient ambulatory ECG monitoring to screen for silent atrial fibrillation: Pilot Findings from Screening Trial for Undiagnosed Atrial Fibrillation (STUDY-AF) Poster Session III
CONCLUSION: Ambulatory screening of asymptomatic arrhythmias using the Zio® Patch is feasible; however the diagnostic yield for silent AF may be low, even among patients with established AF risk factors. Our study found a high prevalence of incidental asymptomatic SVT and NSVT. A larger trial with more targeted enrollment may be required to demonstrate the value of screening for AF. The impact of detecting incidental NSVT or SVT, which themselves could prompt evaluation and may be relevant to development of AF, requires further investigation.
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: Ullal, A. J., Hoang, D. D., Than, C., Heidenreich, P. A., Miller, J. D., Friday, K., Froelicher, V. F., Turakhia, M. P. Tags: Poster Session III Source Type: research

Abstract 227: Prescribing Warfarin at Discharge for Heart Failure Patients without Atrial Fibrillation Findings from the Get With The Guidelines-Heart Failure Registry Poster Session II
Conclusions: Approximately 1 in 10 HF patients without AF or other documented indications are prescribed warfarin at discharge, and prescription rates vary widely across hospitals. Further research is needed to understand why anticoagulation is prescribed to patients with HF in the absence of documented indications.
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: Eapen, Z., Grau-Sepulveda, M., Fonarow, G., Heidenreich, P., Peterson, E., Hernandez, A. Tags: Poster Session II Source Type: research

Abstract 237: Anticoagulant Use For the Prevention of Stroke in Patients with Atrial Fibrillation: Findings From a Multi-Payer Analysis Poster Session II
Conclusions: Many AF patients in selected commercial, Medicare-eligible, and Medicaid populations, including those at high risk of stroke, do not receive appropriate thromboprophylaxis, as recommended by treatment guidelines. Increased use of the analyzer and similar software may support enhanced education efforts aimed at improving adherence to guidelines and quality of care.
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: Lang, K., Bozkaya, D., Patel, A. A., Macomson, B., Nelson, W., Owens, G., Mody, S. Tags: Poster Session II Source Type: research

Abstract 239: Rates of Atrial Fibrillation Diagnoses and Stroke Events by Combination of Risk Factors Poster Session II
Conclusions: Results from a very large sample of patients in a claims database confirm increased rates of AF and stroke in patients with known risk ractors, while adding to the knowledge base regarding the risk levels among many less prevalent combinations of these factors. The results suggest that patients should be monitored more vigilantly as age progresses for signs of AF, and possibly treated more aggressively for risk factors that increase the incidence of AF and stroke. In particular, patients age 75+ may be considered to be at risk based on age alone.
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: Turakhia, M. P., Hunter, T. D., Mollenkopf, S. A., Reynolds, M. R. Tags: Poster Session II Source Type: research

Abstract 241: Design and Clinical Outcomes of INSTOR (Interventional Stroke Therapy Outcomes Registry) Poster Session II
Conclusions: INSTOR presents instant online graphical and numerical results including "door to CT", "door to IV tPA", "time for return of laboratory results" and "time to angiography", etc. Process trends are presented with graphed monthly median data points overlain by a logistic regression trend line. The computerized multisite database also has the capability of automatically sending text massage or email reminders to designated recipients for follow-up events such as discharge information or 90-day mRS. INSTOR instantly performs complex multifactorial analyses of numerous measures of clinical outcomes for both IV tPA a...
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: Connors, J. Tags: Poster Session II Source Type: research

Abstract 243: Impact of Dual Health Care System Use on Quality of Warfarin Anticoagulation in Atrial Fibrillation Poster Session II
Conclusion: More than half of Veterans age ≥ 65 with AF and VA-issued warfarin receive outpatient INR testing in MC. Dual health care system use is associated with lower achievement of process measures of quality of anticoagulation care, which could affect outcomes of stroke, hemorrhage and death.
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: Than, C., Xu, X., Schmitt, S., Frayne, S., Phibbs, C., Holmes, T., Heidenreich, P., Moos, R., Berlowitz, D., Go, A., Turakhia, M. Tags: Poster Session II Source Type: research

Abstract 245: Indirect Comparison of Efficacy and Safety data in Atrial Fibrillation patients treated with Apixaban (Aristotle study) versus Dabigatran (Rely study) based on Chads2 Score Stratification Poster Session II
CONCLUSIONS: This analysis of the published data suggests similar efficacy for both agents when used in AF patients across the Chad2 score categories, however there was a trend for a higher major bleeding risks ( Chads 2 score 0-1 and 2 ) and a statistically significantly higher bleeding event rate (Chads2 score >=3) with DAB.
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: Rasty, S., Taheri, R. Tags: Poster Session II Source Type: research

Abstract 258: Dabigatran Etexilate is Associated with Shorter Hospital Length of Stay and Lower Hospital Costs Compared to Warfarin in Treatment-Naive, Newly-Diagnosed Nonvalvular Atrial Fibrillation Patients Poster Session III
Conclusions: Among hospitalizations of treatment-naive patients newly diagnosed with nonvalvular AF, the hospitalizations during which DE was administered had a shorter LOS and at least a 12% lower total hospital cost compared to hospitalizations where warfarin was administered.
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: Fonseca, E., Walker, D. R., Hess, G. P. Tags: Poster Session III Source Type: research

Pages: 1  2  3  4  5  6  7  8  9